ArticleFrontiers in oncology2026
Salvage resection for FGFR2 fusion-positive intrahepatic cholangiocarcinoma after pemigatinib therapy: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of intrahepatic cholangiocarcinoma (iCCA) is rising. Unfortunately, most patients present with locally advanced or metastatic disease at initial diagnosis, making them ineligible for surgical resection. Currently, the standard first-line treatment for unresectable iCCA is gemcitabine plus cisplatin combined with durvalumab or pembrolizumab, but the survival benefit remains limited. Pemigatinib is recommended as the treatment of previously treated advanced iCCA with FGFR2 fusion or rearrangement. The favorable objective response rate in FIGHT-302 study highlights its potential in salvage resection following tumor shrinkage and downstaging. Salvage resection has been implemented in various initially unresectable malignancies, significantly improving patient prognosis. To date, few reports have described salvage resection following FGFR inhibitor therapy for FGFR2 fusion-positive iCCA. Case presentation: A 66-year-old female diagnosed with locally advanced iCCA harboring Conclusion: This is the first report of salvage resection following first-line pemigatinib monotherapy for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.